Journal of Medicinal Chemistry
Article
(14) Engelman, J. A.; Janne, P. A. Mechanisms of acquired resistance
growth factor receptor irreversible inhibitors: chemical exploration of
the cysteine-trap portion. Mini-Rev. Med. Chem. 2011, 11, 1019−1030.
(29) Zhou, W.; Ercan, D.; Chen, L.; Yun, C.-H.; Li, D.; Capelletti, M;
Cortot, A. B.; Chierac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong,
̈
to epidermal growth factor receptor tyrosine kinase inhibitors in non-
small cell lung cancer. Clin. Cancer Res. 2008, 14, 2895−2899.
(15) Yun, C.-H.; Mengwasser, K. E.; Toms, A. V.; Woo, M. S.;
Greulich, H.; Wong, K.-K.; Meyerson, M.; Eck, M. J. The T790M
mutation in EGFR kinase causes drug resistance by increasing the
affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2070−2075.
(16) Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K.
D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.;
McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-
Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the
epidermal growth factor receptor and erbB2, by a new class of tyrosine
kinase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022−12027.
(17) Blair, J. A.; Rauh, D.; Kung, C.; Yun, C.-H.; Fan, Q.-W.; Rode,
H.; Zhang, C.; Eck, M. J.; Weiss, W. A.; Shokat, K. M. Structure-guided
development of affinity probes for tyrosine kinases using chemical
genetics. Nat. Chem. Biol. 2007, 3, 229−238.
(18) Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.;
Okimoto, R. A.; Branningan, B. W.; Harria, P. L.; Driscoli, D. R.;
Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Sharma,
S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible
inhibitors of the EGF receptor may circumvent acquired resistance to
gefitinib. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 7665−7670.
(19) Carter, T. A.; Wodicka, L. M.; Shah, N. P.; Velasco, A. M.;
Fabian, M. A.; Treiber, D. K.; Milanov, Z. V.; Atteridge, C. E.; Biggs,
V. H.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Grotzfeld, R. M.; Herrgard,
S.; Insko, D. E.; Mehta, S. A.; Patel, H. K.; Pao, W.; Sawyers, C. L.;
Varmus, H.; Zarrinkar, P. P.; Lockhart, D. J. Inhibition of drug-
resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl.
Acad. Sci. U.S.A. 2005, 102, 11011−11016.
(20) Godin-Heymann, N.; Ulkus, L.; Brannigan, B. W.; McDermott,
U.; Lamb, J.; Maheswaran, S.; Settleman, J.; Haber, D. A. The T790M
“gatekeeper” mutation in EGFR mediates resistance to low
concentration of an irreversible EGFR inhibitor. Mol. Cancer Ther.
2008, 7, 874−879.
(21) Slichenmyer, W. J.; Elliott, W. L.; Fry, D. W. CI-1033, a
pan-erbB tyrosine kinase inhibitor. Semin. Oncol. 2001, 28, 80−85.
(22) Minkovsky, N.; Berezov, A. BIBW-2992, a dual receptor
tyrosine kinase inhibitor for the treatment of solid tumours. Curr.
Opin. Invest. Drugs 2008, 9, 1336−1346.
(23) Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.;
Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, D.;
OverBeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.;
Wissner, A. Antitumor activity of HKI-272, an orally active, irreversible
inhibitor of the Her-2 tyrosine kinase. Cancer Res. 2004, 64, 3958−3965.
(24) Singh, J.; Petter, R. C.; Kluge, A. F. Targeted covalent drugs of
the kinase family. Curr. Opin. Chem. Biol. 2010, 14, 475−480.
(25) Tsou, H.-R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber,
B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.;
Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner, A.
6-Substituted-4-(3-bromophenylamino)quinazolines as putative irre-
versible inhibitors of the epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor (HER-2) tyrosine
kinases with enhanced antitumor activity. J. Med. Chem. 2001, 44,
2719−2734.
K.-K.; Eck, M. J.; Gray, N. S.; Janne, P. Novel mutant-selective EGFR
̈
kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070−1074.
(30) Garuti, L.; Roberti, M.; Bottegoni, G. Irreversible protein kinase
inhibitors. Curr. Med. Chem. 2011, 18, 2981−2994.
(31) Janne, P. A.; von Pawel, J.; Cohen, R. B.; Crino, L.; Butts, C. A.;
̈
Olson, S. S.; Eiseman, I. A.; Chiappori, A. A.; Yeap, B. Y.; Lenehan,
P. F.; Dasse, K.; Sheeran, M.; Bonomi, P. D. Multicenter, randomized,
phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for
previously treated advanced non small-cell lung cancer. J. Clin. Oncol.
2007, 25, 3936−3944.
(32) Besse, B.; Eaton, K. D.; Soria, J. C.; Lynch, T. J.; Miller, V.;
Wong, K. K.; Powell, C.; Quinn, S.; Zacharchuk, C.; Sequist, L. V.
Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine
kinase inhibitor: preliminary results of a phase 2 trial in patients with
advanced non-small cell lung cancer. Eur. J. Cancer 2008, Suppl. 6, 64.
(33) Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J. M.; Winssinger,
N. Cysteine mapping in conformationally distinct kinase nucleotide
binding sites: application to the design of selective covalent inhibitors.
J. Med. Chem. 2011, 54, 1347−1355.
(34) Carmi, C.; Cavazzoni, A.; Vezzosi, S.; Bordi, F.; Vacondio, F.;
Silva, C.; Rivara, S.; Lodola, A.; Alfieri, R. R.; La Monica, S.; Galetti,
M.; Ardizzoni, A.; Petronini, P. G.; Mor, M. Novel irreversible
epidermal growth factor receptor inhibitors by chemical modulation of
the cysteine-trap portion. J. Med. Chem. 2010, 53, 2038−2050.
(35) Carmi, C.; Cavazzoni, A.; Zuliani, V.; Lodola, A.; Bordi, F.;
Plazzi, P. V.; Alfieri, R. R.; Petronini, P. G.; Mor, M. 5-Benzylidene-
hydantoins as new EGFR inhibitors with antiproliferative activity.
Bioorg. Med. Chem. Lett. 2006, 16, 4021−4025.
(36) Zuliani, V.; Carmi, C.; Rivara, M.; Fantini, M.; Lodola, A.;
Vacondio, F.; Bordi, F.; Plazzi, P. V.; Cavazzoni, A.; Galetti, M.; Alfieri,
R. R.; Petronini, P. G.; Mor, M. 5-Benzylidene-hydantoins: synthesis
and antiproliferative activity on A549 lung cancer cell line. Eur. J. Med.
Chem. 2009, 44, 3471−3479.
(37) Cavazzoni, A.; Alfieri, R. R.; Carmi, C.; Zuliani, V.; Galetti, M.;
Fumarola, C.; Frazzi, R.; Bonelli, M.; Bordi, F.; Lodola, A.; Mor, M.;
Petronini, P. G. Dual mechanisms of action of the 5-benzylidene-
hydantoin UPR1024 on lung cancer cell lines. Mol. Cancer Ther. 2008,
7, 361−370.
(38) Maresso, A. W.; Wu, R.; Kern, J. W.; Zhang, R.; Janik, D.;
Misiakas, D. M.; Duban, M.-E.; Joachimiak, A.; Schneewind, O.
Activation of inhibitors of sortase triggers irreversible modification of
the active site. J. Biol. Chem. 2007, 282, 23129−23139.
(39) Wenzel, N. I.; Chavain, N.; Wang, Y.; Friebolin, W.; Maes, L.;
Pradines, B.; Lanzer, M.; Yardley, V.; Brun, R.; Herold-Mende, C.;
́
Biot, C.; Toth, K.; Davioud-Charvet, E. Antimalarial versus cytotoxic
properties of dual drugs derived from 4-aminoquinolines and Mannich
bases: interaction with DNA. J. Med. Chem. 2010, 53, 3214−3226.
(40) Hwang, J. Y.; Arnold, L. A.; Zhu, F.; Kosinski, A.; Mangano, T. J.;
Setola, V.; Roth, B. L.; Guy, R. K. Improvement of pharmacological
properties of irreversible thyroid receptor coactivator binding inhibitors.
J. Med. Chem. 2009, 52, 3892−3901.
(26) Smaill, J. B.; Showalter, H. D. H.; Zhou, H.; Bridges, A. J.;
McNamara, D. J.; Fry, D. W.; Nelson, J. M.; Sherwood, V.; Vincent,
P. W.; Roberts, B. J.; Elliott, W. L.; Denny, W. A. Tyrosine kinase
inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido-
[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal
growth factor receptor. J. Med. Chem. 2001, 44, 429−440.
(41) Brown, G. R.; Bamford, A. M.; Bowyer, J.; James, D. S.; Rankine,
N.; Tang, E.; Torr, V.; Culbert, E. J. Naphthyl ketones: a new class of
Janus kinase 3 inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 575−579.
(42) Flynn, G. A.; Lee, S. A.; Faris, M.; Brandt, D. W.; Chakravaty, S.
Intracellular kinase inhibitors. PCT Int. Appl. WO2007/136790, 2007.
(43) Traxler, P.; Trinks, U.; Buchdunger, E.; Mett, H.; Meyer, T.;
Mueller, M.; Regenass, U.; Roesel, J.; Lydon, N. [(Alkylamino)-
methyl]acrylophenones: potent and selective inhibitors of the
epidermal growth factor receptor protein tyrosine kinase. J. Med.
Chem. 1995, 38, 2441−2448.
(44) Neelakantan, S.; Nasim, S.; Guzman, M. L.; Jordan, C. T.;
Crooks, P. A. Aminopartenolides as novel anti-leukemic agents:
discovery of the NF-κB inhibitor, DMAPT (LC-1). Bioorg. Med. Chem.
Lett. 2009, 19, 4346−4349.
(27) Mishani, E.; Abourbeh, G.; Jacobson, O.; Dissoki, S.; Daniel,
R. B.; Rozen, G.; Shaul, M.; Levitzki, A. High-affinity epidermal growth
factor receptor (EGFR) irreversible inhibitors with diminished
chemical reactivities as positron emission tomography (PET)-imaging
agent candidates of EGFR overexpressing tumors. J. Med. Chem. 2005,
48, 5337−5348.
(28) Carmi, C.; Lodola, A.; Rivara, S.; Vacondio, F.; Cavazzoni, A.;
Alfieri, R. R.; Ardizzoni, A.; Petronini, P. G.; Mor, M. Epidermal
2263
dx.doi.org/10.1021/jm201507x | J. Med. Chem. 2012, 55, 2251−2264